SML2824
Valiglurax
≥98% (HPLC)
别名:
N-(1H-Pyrazolo[3,4-b]pyridin-3-yl)-1-(trifluoromethyl)isoquinolin-6-amine, N-1H-Pyrazolo[3,4-b]pyridin-3-yl-1-(trifluoromethyl)-6-isoquinolinamine, VU0652957, VU2957
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C16H10F3N5
化学文摘社编号:
分子量:
329.28
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
SMILES string
FC(F)(F)c1nccc2c1ccc(c2)Nc3n[nH]c4ncccc43
InChI
1S/C16H10F3N5/c17-16(18,19)13-11-4-3-10(8-9(11)5-7-20-13)22-15-12-2-1-6-21-14(12)23-24-15/h1-8H,(H2,21,22,23,24)
InChI key
RUEXKBWCUUFJMY-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
Valiglurax is an orally available, CNS penetrant, potent and selective mGlu4 positive allosteric modulator (PAM).
orally available, CNS penetrant, potent and selective mGlu4 PAM
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Joseph D Panarese et al.
Bioorganic & medicinal chemistry letters, 29(2), 342-346 (2018-12-07)
This letter describes the first account of the chemical optimization (SAR and DMPK profiling) of a new series of mGlu4 positive allosteric modulators (PAMs), leading to the identification of VU0652957 (VU2957, Valiglurax), a compound profiled as a preclinical development candidate.
Joseph D Panarese et al.
ACS medicinal chemistry letters, 10(3), 255-260 (2019-03-21)
Herein, we report the discovery of a novel potent, selective, CNS penetrant, and orally bioavailable mGlu4 PAM, VU0652957 (VU2957, Valiglurax). VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties across species. To advance toward the clinic, a
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持